BRISTOL-MYERS SQUIBB COMPANY Debt Instrument, Fair Value Disclosure
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Debt Instrument, Fair Value Disclosure of $39.20 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFairValue · last filed 2026-07-30
- 2026-06-30: Debt Instrument, Fair Value Disclosure $39.20B.
- 2026-03-31: Debt Instrument, Fair Value Disclosure $40.20B.
- 2025-12-31: Debt Instrument, Fair Value Disclosure $41.50B.
- 2025-09-30: Debt Instrument, Fair Value Disclosure $45.80B.
| Period end | Debt Instrument, Fair Value Disclosure | Debt Instrument, Fair Value Disclosure as first filed |
|---|---|---|
| 2026-06-30 | $39.20B 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $40.20B 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $41.50B 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $45.80B 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $45.50B 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $46.00B 10-Q · filed 2025-04-24 | |
| 2024-12-31 | $45.30B 10-K · filed 2026-02-11 | |
| 2024-09-30 | $47.90B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $47.70B 10-Q · filed 2024-07-26 | |
| 2024-03-31 | $49.20B 10-Q · filed 2024-04-25 | |
| 2023-12-31 | $36.70B 10-K · filed 2025-02-12 | |
| 2023-09-30 | $31.70B 10-Q · filed 2023-10-26 | |
| 2023-06-30 | $33.50B 10-Q · filed 2023-07-27 | |
| 2023-03-31 | $34.50B 10-Q · filed 2023-04-27 | |
| 2022-12-31 | $34.90B 10-K · filed 2024-02-13 | |
| 2022-09-30 | $34.30B 10-Q · filed 2022-10-26 | |
| 2022-06-30 | $39.70B 10-Q · filed 2022-07-27 | |
| 2022-03-31 | $45.80B 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $49.10B 10-K · filed 2023-02-14 | |
| 2021-09-30 | $49.80B 10-Q · filed 2021-10-27 | |
| 2021-06-30 | $50.60B 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $50.30B 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $58.50B 10-K · filed 2022-02-09 | |
| 2020-09-30 | $52.70B 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $53.80B 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $51.90B 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $50.70B 10-K · filed 2021-02-10 | |
| 2019-09-30 | $26.60B 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $25.90B 10-Q · filed 2019-07-25 | |
| 2019-03-31 | $5.90B 10-Q · filed 2019-04-25 | |
| 2018-12-31 | $7.10B 10-K · filed 2020-02-24 | $7.09B 10-K · filed 2019-02-25 |
| 2018-09-30 | $7.10B 10-Q · filed 2018-10-25 | |
| 2018-06-30 | $7.20B 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $7.30B 10-Q · filed 2018-04-26 | |
| 2017-12-31 | $7.45B 10-K · filed 2019-02-25 | |
| 2017-09-30 | $7.40B 10-Q · filed 2017-10-26 | |
| 2017-06-30 | $8.10B 10-Q · filed 2017-07-27 | |
| 2017-03-31 | $8.41B 10-Q · filed 2017-04-27 | |
| 2016-12-31 | $6.93B 10-K · filed 2018-02-13 | |
| 2016-09-30 | $7.49B 10-Q · filed 2016-10-27 | |
| 2016-06-30 | $7.46B 10-Q · filed 2016-07-28 | |
| 2016-03-31 | $7.24B 10-Q · filed 2016-04-28 | |
| 2015-12-31 | $6.91B 10-K · filed 2017-02-21 | |
| 2015-09-30 | $6.93B 10-Q · filed 2015-10-27 | |
| 2015-06-30 | $6.80B 10-Q · filed 2015-07-23 | |
| 2015-03-31 | $8.06B 10-Q · filed 2015-04-28 | |
| 2014-12-31 | $8.04B 10-K · filed 2016-02-12 | |
| 2014-09-30 | $7.92B 10-Q · filed 2014-10-24 | |
| 2014-06-30 | $8.01B 10-Q · filed 2014-07-24 | |
| 2014-03-31 | $7.91B 10-Q · filed 2014-04-29 | |
| 2013-12-31 | $8.49B 10-K · filed 2015-02-13 | |
| 2013-09-30 | $7.11B 10-Q · filed 2013-10-23 | |
| 2013-06-30 | $7.72B 10-Q · filed 2013-07-25 | |
| 2013-03-31 | $8.11B 10-Q · filed 2013-04-25 | |
| 2012-12-31 | $8.29B 10-K · filed 2014-02-14 | |
| 2012-09-30 | $8.35B 10-Q · filed 2012-10-24 | |
| 2012-06-30 | $6.29B 10-Q · filed 2012-07-25 | |
| 2011-12-31 | $6.41B 10-K · filed 2013-02-15 | |
| 2010-12-31 | $5.86B 10-K · filed 2012-02-17 | |
| 2009-12-31 | $6.26B 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |